HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 323 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8 | -72.4% | 211 | -73.9% | 0.00% | – |
| Q2 2023 | $29 | +383.3% | 807 | +366.5% | 0.00% | – |
| Q1 2023 | $6 | -97.7% | 173 | -96.2% | 0.00% | -100.0% |
| Q4 2022 | $262 | -95.6% | 4,591 | +3133.1% | 0.00% | – |
| Q3 2022 | $6,000 | -53.8% | 142 | -57.0% | 0.00% | – |
| Q4 2021 | $13,000 | 0.0% | 330 | 0.0% | 0.00% | – |
| Q3 2021 | $13,000 | -13.3% | 330 | 0.0% | 0.00% | – |
| Q2 2021 | $15,000 | -53.1% | 330 | -56.6% | 0.00% | – |
| Q1 2021 | $32,000 | -15.8% | 760 | -15.6% | 0.00% | – |
| Q4 2020 | $38,000 | +11.8% | 900 | -30.8% | 0.00% | – |
| Q3 2020 | $34,000 | -37.0% | 1,300 | -35.0% | 0.00% | – |
| Q2 2020 | $54,000 | -85.6% | 2,000 | -89.6% | 0.00% | -100.0% |
| Q1 2018 | $376,000 | -3.1% | 19,172 | 0.0% | 0.00% | -50.0% |
| Q4 2017 | $388,000 | – | 19,172 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |